A Trial Assessing The Effectiveness and Safety of [S,S]-Reboxetine in Patients With Fibromyalgia

Summary

The purpose of this study is to assess the safety and effectiveness of \[S,S\]-Reboxetine in patients with fibromyalgia.

Timeline

Start

2006-08

Primary completion

2007-03

Completion

2007-03

Outcome

Met primary endpoint

paper The esreboxetine group had significantly greater improvement in the weekly mean pain score compared with the placebo group PMID 20974319 ↗

paper weekly mean pain score compared with the placebo group (mean [SE] change from baseline: -1.55 [0.16] vs -0.99 [0.16], respectively; P = 0.006). PMID 20974319 ↗

release “267 patients with fibromyalgia treated with esreboxetine (dose escalated to 8 mg/day) or placebo for 8 weeks, the study met its primary endpoint” pfizer.com ↗

Publications

• Arnold LM, Chatamra K, Hirsch I, Stoker M. Safety and efficacy of esreboxetine in patients with fibromyalgia: An 8-week, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2010 Aug;32(9):1618-32. doi: 10.1016/j.clinthera.2010.08.003.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	[S,S]-Reboxetine	Unknown	8 mg	—

Indications

No indication recorded.